Abstract
Patient was a 52-year-old woman presented with shortness of breath, NYHA class II.
She was diagnosed with stage 3 invasive ductal carcinoma of the left breast and lymph node metastatic disease, received adjuvant chemotherapy with doxorubicin and cyclophosphamide, four cycles, and paclitaxel plus trastuzumab three cycles; Consequently, cycle four canceled because of reported ejection fraction of 40% on echocardiogram. She was started on carvedilol and ramipril for heart failure with mid-range LVEF. Then after she completed radiotherapy; follow up echocardiogram showed an ejection fraction of 53%, so her adjuvant trastuzumab chemotherapy resumed, and she received three more cycles of adjuvant trastuzumab alone. Her trastuzumab was put on hold again because of ejection fraction of 48% and then discontinued permanently. On follow up the patient has no symptoms suspicious for recurrence of her breast cancer. Her LVEF also improved to 50% while on both carvedilol and ramipril.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, Ewer MS, Rathi V, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(31):3792.
Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M. Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients. JACC Cardiovasc Imaging. 2018;11(8):1084–93. https://doi.org/10.1016/j.jcmg.2018.06.005.
Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA. Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial. J Clin Oncol. 2016;34(6):581–7. https://doi.org/10.1200/JCO.2015.61.8413.
Bria E, Cuppone F, Fornier M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat. 2008;109(2):231–9. https://doi.org/10.1007/s10549-007-9663-z.
Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol. 2010;28(21):3416–21. https://doi.org/10.1200/JCO.2009.23.6950.
Yu AF, Yadav NU, Lung BY, et al. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Breast Cancer Res Treat. 2015;149:489–95.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Rohani, A. (2021). Trastuzumab-Related Cardiotoxicity. In: Clinical Cases in Cardio-Oncology. Clinical Cases in Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-71155-9_7
Download citation
DOI: https://doi.org/10.1007/978-3-030-71155-9_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-71154-2
Online ISBN: 978-3-030-71155-9
eBook Packages: MedicineMedicine (R0)